At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 5, 2026 at 07:30 ET
SAB Biotherapeutics reported a Q3 2026 net loss of $22.3M vs net income of $45.4M a year ago, driven by higher R&D and G&A costs for its lead T1D candidate SAB-142. The registrational SAFEGUARD study is on track for full enrollment in Q4 2026 with topline data expected in 2H 2027, and the company received FDA Fast Track designation for SAB-142 in October 2026. Cash of $205.3M provides runway through 2028, but the net loss widened significantly from a year-ago period that included a $58.1M non-cash gain.
- Net loss of $22.3M for Q3 2026 vs net income of $45.4M in Q3 2025 (prior year included $58.1M non-cash gain from warrant liability revaluation)
- R&D expenses $18.1M (Q3 2026) vs $9.0M (Q3 2025), driven by clinical trial costs and headcount for SAB-142
- G&A expenses $7.8M (Q3 2026) vs $3.7M (Q3 2025), driven by personnel costs including stock-based compensation
- Cash, cash equivalents and investment securities $205.3M at September 30, 2026, providing operational runway through 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access